Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Restenosis Clear all
Completed No phase listed Observational Results available

Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease

NCT04229563
View directory record Official record
Conditions
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
Interventions
AURYON Atherectomy System
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Davenport, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 22, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Prevention of Restenosis Following Revascularization

NCT00518284
View directory record Official record
Conditions
Vascular Disease, Peripheral
Interventions
Nanoparticle Paclitaxel
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Sacramento, California • Gainsville, Florida • Davenport, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

The ELUTES Clinical Trial

NCT00225654
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

In-Stent Restenosis Post-Approval Study

NCT02542267
View directory record Official record
Conditions
Peripheral Artery Disease, Vascular Disease
Interventions
Gore VIABAHN Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
20
States / cities
Miami, Florida • Honolulu, Hawaii • Rockford, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional

The SOS (Stenting Of Saphenous Vein Grafts) Trial

NCT00247208
View directory record Official record
Conditions
Coronary Artery Bypass, Arteriosclerosis
Interventions
Taxus polymer-based paclitaxel-eluting stent, Express 2 bare metal stent
Device
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Little Rock, Arkansas • Iowa City, Iowa • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

NCT02790606
View directory record Official record
Conditions
Stenosis, Restenosis
Interventions
Covera(TM) Vascular Covered Stent
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 22, 2026, 10:19 AM EDT
Not listed Phase 2 Interventional

Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis

NCT03106948
View directory record Official record
Conditions
Arteriovenous Fistula Occlusion
Interventions
Placebo, Ascorbic Acid, Cuprimine Oral Product
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 22, 2026, 10:19 AM EDT
Not listed Not applicable Interventional

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

NCT01599078
View directory record Official record
Conditions
Restenosis, Peripheral Arterial Disease
Interventions
Paclitaxel, Placebo
Drug
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bettendorf, Iowa
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Sep 22, 2026, 10:19 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)

NCT01120379
View directory record Official record
Conditions
Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
5,034 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 22, 2026, 10:19 AM EDT
Not listed No phase listed Observational

Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation

NCT01835301
View directory record Official record
Conditions
In-stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions

NCT00301522
View directory record Official record
Conditions
Coronary Stenosis
Interventions
TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Sep 22, 2026, 10:19 AM EDT
Not listed No phase listed Observational

Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System

NCT00852176
View directory record Official record
Conditions
Coronary In-stent Restenosis
Interventions
Not listed
Lead sponsor
Best Vascular, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

STAR and Deferred Stenting Study

NCT05089864
View directory record Official record
Conditions
Coronary Occlusion, Coronary Stenosis, Coronary Restenosis
Interventions
Stent Placement Timing - Early, Stent Placement Timing - Late
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

NCT01270945
View directory record Official record
Conditions
Patients Undergoing Repeat Peripheral Artery Revascularization
Interventions
CV-18C3, Standard of Care
Drug · Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Sacramento, California • Atlantis, Florida • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 22, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

NCT00001531
View directory record Official record
Conditions
Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional Results available

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)

NCT01923740
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
XIENCE V EECSS, Absorb BVS System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries

NCT03192696
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Atherectomy Catheter
Device
Lead sponsor
Avinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 22, 2026, 10:19 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Phase 4 Interventional

Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty

NCT00162357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Coronary Restenosis
Interventions
Technetium Tc99m Sestamibi
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
7
States / cities
Hartford, Connecticut • Waterbury, Connecticut • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 22, 2026, 10:19 AM EDT
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 22, 2026, 10:19 AM EDT
Terminated Not applicable Interventional

Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis

NCT00712257
View directory record Official record
Conditions
Restenosis
Interventions
Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface
Device
Lead sponsor
VIVA Physicians
Other
Eligibility
18 Years to 89 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 22, 2026, 10:19 AM EDT